company background image
PRTA

ProthenaNasdaqGS:PRTA Stock Report

Market Cap

US$3.4b

7D

-2.3%

1Y

642.8%

Updated

26 Sep, 2021

Data

Company Financials +
PRTA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PRTA Overview

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for Prothena
Historical stock prices
Current Share PriceUS$75.32
52 Week HighUS$9.67
52 Week LowUS$78.95
Beta1.49
1 Month Change10.55%
3 Month Change54.57%
1 Year Change642.80%
3 Year Change475.84%
5 Year Change25.60%
Change since IPO946.11%

Recent News & Updates

Aug 09
We're Interested To See How Prothena (NASDAQ:PRTA) Uses Its Cash Hoard To Grow

We're Interested To See How Prothena (NASDAQ:PRTA) Uses Its Cash Hoard To Grow

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Prothena...

Shareholder Returns

PRTAUS BiotechsUS Market
7D-2.3%-2.3%0.1%
1Y642.8%26.0%35.3%

Return vs Industry: PRTA exceeded the US Biotechs industry which returned 26% over the past year.

Return vs Market: PRTA exceeded the US Market which returned 35.3% over the past year.

Price Volatility

Is PRTA's price volatile compared to industry and market?
PRTA volatility
PRTA Beta1.49
Industry Beta1.03
Market Beta1

Stable Share Price: PRTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PRTA's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201266Gene Kinneyhttps://www.prothena.com

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson’s disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; Aß, or Amyloid Beta, a protein for the treatment of Alzheimer’s disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases.

Prothena Fundamentals Summary

How do Prothena's earnings and revenue compare to its market cap?
PRTA fundamental statistics
Market CapUS$3.39b
Earnings (TTM)-US$70.39m
Revenue (TTM)US$60.75m

55.9x

P/S Ratio

-48.2x

P/E Ratio

Valuation

Is Prothena undervalued compared to its fair value and its price relative to the market?

11.77x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: PRTA ($75.32) is trading above our estimate of fair value ($48.13)

Significantly Below Fair Value: PRTA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PRTA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: PRTA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRTA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRTA is overvalued based on its PB Ratio (11.8x) compared to the US Biotechs industry average (3.3x).


Future Growth

How is Prothena forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

-22.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PRTA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PRTA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PRTA's revenue (4.1% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: PRTA's revenue (4.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PRTA is forecast to be unprofitable in 3 years.


Past Performance

How has Prothena performed over the past 5 years?

12.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRTA is currently unprofitable.

Growing Profit Margin: PRTA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRTA is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.

Accelerating Growth: Unable to compare PRTA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: PRTA has a negative Return on Equity (-24.42%), as it is currently unprofitable.


Financial Health

How is Prothena's financial position?


Financial Position Analysis

Short Term Liabilities: PRTA's short term assets ($409.5M) exceed its short term liabilities ($52.9M).

Long Term Liabilities: PRTA's short term assets ($409.5M) exceed its long term liabilities ($95.3M).


Debt to Equity History and Analysis

Debt Level: PRTA is debt free.

Reducing Debt: PRTA has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRTA has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PRTA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Prothena current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Gene Kinney (52 yo)

5yrs

Tenure

US$3,427,567

Compensation

Mr. Gene G. Kinney, Ph D., has been the Chief Executive Officer and President of Prothena Corporation plc since September 26, 2016 and October 3, 2016 respectively and served as its Chief Operating Officer...


CEO Compensation Analysis

Compensation vs Market: Gene's total compensation ($USD3.43M) is below average for companies of similar size in the US market ($USD5.28M).

Compensation vs Earnings: Gene's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PRTA's management team is considered experienced (4.3 years average tenure).


Board Members

Experienced Board: PRTA's board of directors are considered experienced (7.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.9%.


Top Shareholders

Company Information

Prothena Corporation plc's employee growth, exchange listings and data sources


Key Information

  • Name: Prothena Corporation plc
  • Ticker: PRTA
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$3.393b
  • Shares outstanding: 45.05m
  • Website: https://www.prothena.com

Number of Employees


Location

  • Prothena Corporation plc
  • 77 Sir John Rogerson’s Quay
  • Block C
  • Dublin
  • Co. Dublin
  • 2
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/26 22:17
End of Day Share Price2021/09/24 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.